Paget’s Disease - Drug Pipeline Analysis and Market Forecasts to 2016

The Paget’s Disease Market is Forecast to Show a Negative Growth Rate

Online PR News – 12-March-2010 – – GlobalData’s analysis reveals that the Paget’s disease market was worth $159.2m in 2009. It is forecast to exhibit a negative compound annual growth rate (CAGR) of 8.9% for the next seven years and is expected to reach $82.3m by 2016. The negative growth rate is primarily attributable to a weak pipeline. Furthermore, a substantial decrease in the prevalence of Paget’s disease will lead to a drop in the global prescription population. The market is also predicted to witness generic erosion owing to the patent expiry of products such as Actonel and Fosamax. The market has been steadily declining over the past few years and this trend is likely to continue.

For further details, please click or add the below link to your browser:

GlobalData found the current competition in the Paget’s disease market to be strong. Since the market is governed by both branded and generics that fall under the same class of drugs– bisphosphonates – they have comparable safety and efficacy profiles. This apart, products such as Skelid, which recently lost its patent in 2009, already have generic versions available in the market which are much lower priced than the original molecule. The situation is expected to be repeated again when Actonel and Fosamax lose their respective patent protection. This will certainly lead to a loss in revenues and the market share war in this declining market will become more intense. Also, as no new molecules are likely to enter the market in the next few years and cause a major impact, a negative growth rate is expected until 2016.

For further details, please click or add the below link to your browser:

GlobalData found that that the presently available treatment options are moderately successful in meeting patient requirements. Although the drugs that are currently prescribed are primarily used to alleviate symptoms rather than provide a permanent cure to patients, they have been used in patients with Paget’s disease and have yielded beneficial therapeutic outcomes. However, the unmet need in terms of safety and efficacy in this market is low since bisphosphonates are known to cause no major adverse events in patients if the dosing schedule is appropriately adhered to. The clinical unmet need is therefore likely to remain unaltered over the next few years. There is also a possibility that the unmet need may increase as no new drugs are expected to enter the market in the next few years. Reports suggest that the patients are likely to elicit a weaker pharmacological response to drugs upon prolonged exposure. Hence, higher doses, or drugs with more bioavailability will be required to elicit a response in certain groups of patients. Since no new drugs are currently available in the therapeutic pipeline an increase in the clinical unmet need may also be expected.

GlobalData, the industry analysis specialist, has released its new report, “Paget’s Disease – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global Paget’s disease market. The report identifies the key trends shaping and driving the market, and provides insight on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Paget’s disease sector.

For further details, please click or add the below link to your browser:

Or visit our report store: